-
1
-
-
0037108228
-
Policy developments in regulatory approval
-
Temple R. Policy developments in regulatory approval. Stat Med 21 (2002) 2939-2948
-
(2002)
Stat Med
, vol.21
, pp. 2939-2948
-
-
Temple, R.1
-
3
-
-
0027076295
-
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
-
Green S., and Weiss G. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10 (1992) 239-253
-
(1992)
Invest New Drugs
, vol.10
, pp. 239-253
-
-
Green, S.1
Weiss, G.2
-
4
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.2
Eisenhauer, E.3
-
5
-
-
33747830466
-
Comparison of RECIST and WHO response criteria in metastatic colorectal carcinoma
-
Choi J., Ahn M., Rhim H., et al. Comparison of RECIST and WHO response criteria in metastatic colorectal carcinoma. J Clin Oncol 23 suppl (2005) 16S
-
(2005)
J Clin Oncol
, vol.23
, Issue.SUPPL
-
-
Choi, J.1
Ahn, M.2
Rhim, H.3
-
7
-
-
24644506259
-
Objective response rate as a surrogate end point: a commentary
-
Fleming T. Objective response rate as a surrogate end point: a commentary. J Clin Oncol 23 (2005) 4845-4846
-
(2005)
J Clin Oncol
, vol.23
, pp. 4845-4846
-
-
Fleming, T.1
-
8
-
-
33644834827
-
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
-
Sargent D., Wieand H., Haller D., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23 (2005) 8664-8670
-
(2005)
J Clin Oncol
, vol.23
, pp. 8664-8670
-
-
Sargent, D.1
Wieand, H.2
Haller, D.3
-
9
-
-
2542615200
-
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
-
Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
-
(2004)
N Engl J Med
, vol.350
, pp. 2343-2351
-
-
Andre, T.1
Boni, C.2
Mounedji-Boudiaf, L.3
-
10
-
-
5044233596
-
-
Alderson P., Green S., and Higgins J. (Eds), John Wiley and Sons, Chichester, UK
-
In: Alderson P., Green S., and Higgins J. (Eds). Cochrane reviewers' handbook 4.2.2 [updated March, 2004]. The Cochrane Library, Issue 2, Section 5 (2004), John Wiley and Sons, Chichester, UK
-
(2004)
Cochrane reviewers' handbook 4.2.2 [updated March, 2004]. The Cochrane Library, Issue 2, Section 5
-
-
-
11
-
-
85047692188
-
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
-
Schulz K., Chalmers I., Hayes R., and Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995) 408-412
-
(1995)
JAMA
, vol.273
, pp. 408-412
-
-
Schulz, K.1
Chalmers, I.2
Hayes, R.3
Altman, D.4
-
13
-
-
33745203168
-
-
Burzykowski T., and Buyse M. (Eds). Burzykowski T., Molenberghs G., and Buyse M. (Eds), Springer, New York
-
In: Burzykowski T., and Buyse M. (Eds). An alternative measure for meta-analytic surrogate endpoint validation. In: Burzykowski T., Molenberghs G., and Buyse M. (Eds). The evaluation of surrogate endpoints (2005), Springer, New York
-
(2005)
The evaluation of surrogate endpoints
-
-
-
14
-
-
33748086937
-
The evaluation of surrogate endpoints in practice: experience in HIV
-
Burzykowski T., Molenberghs G., and Buyse M. (Eds), Springer, New York
-
Hughes M. The evaluation of surrogate endpoints in practice: experience in HIV. In: Burzykowski T., Molenberghs G., and Buyse M. (Eds). The evaluation of surrogate endpoints (2005), Springer, New York
-
(2005)
The evaluation of surrogate endpoints
-
-
Hughes, M.1
-
15
-
-
0034729931
-
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer
-
Buyse M., Thirion P., Carlson R., et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356 (2000) 373-378
-
(2000)
Lancet
, vol.356
, pp. 373-378
-
-
Buyse, M.1
Thirion, P.2
Carlson, R.3
-
16
-
-
24644440601
-
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
-
Bruzzi P., Del Mastro L., Sormani M., et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23 (2005) 5117-5125
-
(2005)
J Clin Oncol
, vol.23
, pp. 5117-5125
-
-
Bruzzi, P.1
Del Mastro, L.2
Sormani, M.3
-
17
-
-
0037083255
-
Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head
-
Berlin J., Santanna J., Schmid C., et al. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 21 (2002) 371-387
-
(2002)
Stat Med
, vol.21
, pp. 371-387
-
-
Berlin, J.1
Santanna, J.2
Schmid, C.3
|